#United States #Cancer Prevention #South San Francisco #Human Longevity #Colon Cancer

Human Longevity Boosts Cancer Commitment to Transform Colon Cancer Detection

In an ambitious move, Human Longevity, Inc. (HLI), recognized as a leader in precision health and longevity medicine, has broadened its $1 million cancer pledge to specifically target colon cancer. This expansion emphasizes the organization's dedication to catching diseases early when effective treatments can significantly improve survival rates.

By enhancing their focus on colon cancer, HLI is introducing a pivotal shift in how cancer screening and prevention are approached. Colon cancer represents a major global health concern, being one of the leading causes of cancer-related fatalities. Yet, it is profoundly preventable if detected at an early stage. Historical practices have predominantly utilized age-based screening schedules and conventional procedures such as colonoscopies to identify tumors, often after they are already established. Unfortunately, there isn't a single test capable of identifying the early development of colon cancer, particularly when it manifests at a molecular level or occurs in areas not easily visualized. HLI's expanded cancer pledge aims to confront these challenges head-on by moving the screening process upstream toward genuinely proactive prevention.

Whole genome sequencing will take center stage in this new initiative. This technology is pivotal for identifying both inherited single-gene risks and complex polygenic risks associated with colon cancer, often years ahead of any noticeable symptoms. Moreover, when paired with advanced imaging techniques, biomarker analyses, and molecular screenings, genome insights offer a comprehensive, personalized risk assessment — elevating the strategy from merely following age guidelines.

A recent case illustrates the effectiveness of this integrated strategy. A patient underwent a routine colonoscopy that returned normal results. However, results from the GRAIL blood test and the Cologuard stool DNA test were both positive. Subsequent evaluations revealed cancer in the appendix, a site often overlooked during standard procedures, reinforcing the critical need for a multifaceted approach to risk assessment.

HLI's cancer detection framework delivers one of the most sophisticated platforms available, combining:

• - Whole genome sequencing for assessing both monogenic and polygenic risks.
• - Advanced full-body MRI and targeted imaging capabilities.
• - Multi-cancer blood screenings, such as GRAIL.
• - Non-invasive stool DNA tests like Cologuard.
• - Ongoing biomarker monitoring.
• - Advanced AI analytics tailored for personalized health insights.

This holistic approach facilitates earlier identification of risks, enhances detection accuracy, and ensures timely clinical interventions — ultimately providing members with the best prospects for preventing colon cancer or identifying it in its nascent stages.

To engage with this initiative, participants enrolled in HLI’s Executive Health Program or one of the affiliated 100+ Longevity Programs will receive tailor-made screening plans. Should a member face a late-stage colon cancer diagnosis while actively participating, they will be qualified for up to $1 million in structured clinical assistance, which encompasses specialist consultations and treatment navigation services.

Dr. Wei-Wu He, Executive Chairman of Human Longevity, remarked, "Our mission is to detect colon cancer before it poses a life-threatening risk. Early detection encompasses more than relying on a singular test; it necessitates an integrated approach comprising accurate clinical insights from multiple methods to empower our members with the greatest chance to prevent or identify disease early."

Founded in 2013, Human Longevity, Inc. stands at the vanguard of combining genomics, artificial intelligence, and multimodal diagnostics, all aimed at prolonging human healthspan. With their flagship Executive Health Program and over 100 Longevity Programs in place, HLI is committed to delivering thorough and data-driven evaluations that focus on identifying and averting diseases long before symptoms appear. To explore more about this initiative or find enrollment details, visit www.humanlongevity.com.